249 related articles for article (PubMed ID: 34873287)
1. Metabolic disorders, COVID-19 and vaccine-breakthrough infections.
Stefan N
Nat Rev Endocrinol; 2022 Feb; 18(2):75-76. PubMed ID: 34873287
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
3. Scientists see a 'really, really tough winter' with Omicron.
Kupferschmidt K
Science; 2021 Dec; 374(6574):1421-1422. PubMed ID: 34914506
[No Abstract] [Full Text] [Related]
4. Host factors and vaccine efficacy: Implications for COVID-19 vaccines.
Falahi S; Kenarkoohi A
J Med Virol; 2022 Apr; 94(4):1330-1335. PubMed ID: 34845730
[TBL] [Abstract][Full Text] [Related]
5. The long road.
Cohen J
Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
[No Abstract] [Full Text] [Related]
6. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
7. Omicron likely to weaken COVID vaccine protection.
Callaway E
Nature; 2021 Dec; 600(7889):367-368. PubMed ID: 34880488
[No Abstract] [Full Text] [Related]
8. Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City.
Duerr R; Dimartino D; Marier C; Zappile P; Wang G; Lighter J; Elbel B; Troxel AB; Heguy A
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34375308
[TBL] [Abstract][Full Text] [Related]
9. Oldest Adults Need 2 mRNA Vaccine Doses to Neutralize SARS-CoV-2.
Abbasi J
JAMA; 2021 Aug; 326(6):473. PubMed ID: 34374737
[No Abstract] [Full Text] [Related]
10. Could new COVID variants undermine vaccines? Labs scramble to find out.
Callaway E
Nature; 2021 Jan; 589(7841):177-178. PubMed ID: 33432212
[No Abstract] [Full Text] [Related]
11. Omicron sparks a vaccine strategy debate.
Cohen J
Science; 2021 Dec; 374(6575):1544-1545. PubMed ID: 34941399
[No Abstract] [Full Text] [Related]
12. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
[No Abstract] [Full Text] [Related]
13. Considerations in boosting COVID-19 vaccine immune responses.
Krause PR; Fleming TR; Peto R; Longini IM; Figueroa JP; Sterne JAC; Cravioto A; Rees H; Higgins JPT; Boutron I; Pan H; Gruber MF; Arora N; Kazi F; Gaspar R; Swaminathan S; Ryan MJ; Henao-Restrepo AM
Lancet; 2021 Oct; 398(10308):1377-1380. PubMed ID: 34534516
[No Abstract] [Full Text] [Related]
14. Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines.
Al Jalali V; Scherzer S; Zeitlinger M
Clin Microbiol Infect; 2021 Oct; 27(10):1529-1530. PubMed ID: 34192576
[No Abstract] [Full Text] [Related]
15. Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections.
Ahmad L
Front Immunol; 2021; 12():742167. PubMed ID: 34804022
[TBL] [Abstract][Full Text] [Related]
16. [Immune memory against SARS-CoV-2: Antibodies against the initial infection and memory B cells for the future ones].
Reynaud CA; Weill JC; Chappert P; Mahévas M
Med Sci (Paris); 2021; 37(8-9):722-725. PubMed ID: 34346865
[No Abstract] [Full Text] [Related]
17. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients.
Deng Y; Li Y; Yang R; Tan W
Cell Mol Immunol; 2021 Aug; 18(8):2040-2041. PubMed ID: 34267334
[No Abstract] [Full Text] [Related]
18. New Omicron strains may portend big COVID-19 waves.
Vogel G
Science; 2022 Sep; 377(6614):1479. PubMed ID: 36173845
[TBL] [Abstract][Full Text] [Related]
19. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
20. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants.
Edara VV; Pinsky BA; Suthar MS; Lai L; Davis-Gardner ME; Floyd K; Flowers MW; Wrammert J; Hussaini L; Ciric CR; Bechnak S; Stephens K; Graham BS; Bayat Mokhtari E; Mudvari P; Boritz E; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Douek DC; Sahoo MK; Sibai M; Solis D; Webby RJ; Jeevan T; Fabrizio TP
N Engl J Med; 2021 Aug; 385(7):664-666. PubMed ID: 34233096
[No Abstract] [Full Text] [Related]
[Next] [New Search]
